Triple Helix Compassion
Advanced gene and cell therapies are expensive, and cost should not decide which children get treated.
Triple Helix Compassion is run through BioHelix NP, our sister nonprofit, to help patients who could benefit from these therapies but cannot pay for them. An independent board reviews each application. It looks at the patient’s medical need, how suitable the patient is for treatment, and the family’s financial situation, and then decides what support to offer, from partial help up to full coverage of treatment costs. Children with serious and rare conditions are the main focus, because they have the most years of life to gain and the fewest other treatment options.
How BioHelix NP Allocates Treatment Grants
Independent clinical evaluation ensuring medical necessity and equity.
An independent board reviews each application. It looks at the patient’s medical need, how suitable the patient is for treatment, and the family’s financial situation, and then decides what support to offer, from partial help up to full coverage of treatment costs. Children with serious and rare conditions are the main focus, because they have the most years of life to gain and the fewest other treatment options.
Objective Eligibility Criteria
Candidacy is judged on confirmed molecular pathology and therapeutic suitability, not influence.
Full and Partial Subsidy Tiers
Coverage can encompass vector synthesis, hospital stay, procedural delivery, and post-treatment monitoring.
Focus on Pediatric Rare Disease
Prioritizing monogenic and neurodevelopmental conditions where early intervention alters the lifespan.
Compassion Mission Statement
“Advanced gene and cell therapies are expensive, and cost should not decide which children get treated.”
Submit a Compassionate Access Application
Physicians, hospital social workers, and families can submit clinical records and financial assistance requests directly to the BioHelix NP intake board.